Cargando…
COVID-19 with rheumatic diseases: a report of 5 cases
The coronavirus disease 2019 (COVID-19), the result of an infection with the new virus, SARS-CoV-2, is rapidly spreading worldwide. It is largely unknown whether the occurrence of COVID-19 in patients with rheumatic immune diseases has some specific manifestations, or makes them more prone to rapidl...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220846/ https://www.ncbi.nlm.nih.gov/pubmed/32406001 http://dx.doi.org/10.1007/s10067-020-05160-x |
_version_ | 1783533246163714048 |
---|---|
author | Cheng, Chuanfang Li, Chuanjing Zhao, Tao Yue, Jing Yang, Fang Yan, Yimin Liu, Xiaoan |
author_facet | Cheng, Chuanfang Li, Chuanjing Zhao, Tao Yue, Jing Yang, Fang Yan, Yimin Liu, Xiaoan |
author_sort | Cheng, Chuanfang |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19), the result of an infection with the new virus, SARS-CoV-2, is rapidly spreading worldwide. It is largely unknown whether the occurrence of COVID-19 in patients with rheumatic immune diseases has some specific manifestations, or makes them more prone to rapidly progress into severe COVID-19. In this case report, we describe the clinical features of 5 rheumatic immune disease patients with the concomitant presence of COVID-19. Amongst these patients, 4 had rheumatoid arthritis (RA) and 1 had systemic sclerosis (SSc). Two patients had a history of close contact with a COVID-19 patient. The age of the patients ranged between 51 and 79 years. Fever (80%), cough (80%), dyspnea (40%), and fatigue (20%) were the most common presenting symptoms. Laboratory investigations revealed leukopenia and lymphopenia in 2 patients. In all the patients, chest computerized tomography (CT) revealed patchy ground glass opacities in the lungs. During the hospital stay, the condition of two patients remained the same (i.e., mild COVID-19), two patients progressed to the severe COVID-19, and one patient worsened to the critically ill COVID-19. These patients were treated with antiviral agents for COVID-19, antibiotics for secondary bacterial infections, and immunomodulatory agents for rheumatic immune diseases. All the patients responded well, were cured of COVID-19, and subsequently discharged. |
format | Online Article Text |
id | pubmed-7220846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer London |
record_format | MEDLINE/PubMed |
spelling | pubmed-72208462020-05-14 COVID-19 with rheumatic diseases: a report of 5 cases Cheng, Chuanfang Li, Chuanjing Zhao, Tao Yue, Jing Yang, Fang Yan, Yimin Liu, Xiaoan Clin Rheumatol Case Based Review The coronavirus disease 2019 (COVID-19), the result of an infection with the new virus, SARS-CoV-2, is rapidly spreading worldwide. It is largely unknown whether the occurrence of COVID-19 in patients with rheumatic immune diseases has some specific manifestations, or makes them more prone to rapidly progress into severe COVID-19. In this case report, we describe the clinical features of 5 rheumatic immune disease patients with the concomitant presence of COVID-19. Amongst these patients, 4 had rheumatoid arthritis (RA) and 1 had systemic sclerosis (SSc). Two patients had a history of close contact with a COVID-19 patient. The age of the patients ranged between 51 and 79 years. Fever (80%), cough (80%), dyspnea (40%), and fatigue (20%) were the most common presenting symptoms. Laboratory investigations revealed leukopenia and lymphopenia in 2 patients. In all the patients, chest computerized tomography (CT) revealed patchy ground glass opacities in the lungs. During the hospital stay, the condition of two patients remained the same (i.e., mild COVID-19), two patients progressed to the severe COVID-19, and one patient worsened to the critically ill COVID-19. These patients were treated with antiviral agents for COVID-19, antibiotics for secondary bacterial infections, and immunomodulatory agents for rheumatic immune diseases. All the patients responded well, were cured of COVID-19, and subsequently discharged. Springer London 2020-05-14 2020 /pmc/articles/PMC7220846/ /pubmed/32406001 http://dx.doi.org/10.1007/s10067-020-05160-x Text en © International League of Associations for Rheumatology (ILAR) 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Case Based Review Cheng, Chuanfang Li, Chuanjing Zhao, Tao Yue, Jing Yang, Fang Yan, Yimin Liu, Xiaoan COVID-19 with rheumatic diseases: a report of 5 cases |
title | COVID-19 with rheumatic diseases: a report of 5 cases |
title_full | COVID-19 with rheumatic diseases: a report of 5 cases |
title_fullStr | COVID-19 with rheumatic diseases: a report of 5 cases |
title_full_unstemmed | COVID-19 with rheumatic diseases: a report of 5 cases |
title_short | COVID-19 with rheumatic diseases: a report of 5 cases |
title_sort | covid-19 with rheumatic diseases: a report of 5 cases |
topic | Case Based Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220846/ https://www.ncbi.nlm.nih.gov/pubmed/32406001 http://dx.doi.org/10.1007/s10067-020-05160-x |
work_keys_str_mv | AT chengchuanfang covid19withrheumaticdiseasesareportof5cases AT lichuanjing covid19withrheumaticdiseasesareportof5cases AT zhaotao covid19withrheumaticdiseasesareportof5cases AT yuejing covid19withrheumaticdiseasesareportof5cases AT yangfang covid19withrheumaticdiseasesareportof5cases AT yanyimin covid19withrheumaticdiseasesareportof5cases AT liuxiaoan covid19withrheumaticdiseasesareportof5cases |